¹û¶³Ó°Ôº

XClose

EMINENT CONSORTIUM

Home
Menu

Experimental Medicine Initiative to Explore New Therapies (EMINENT)

EMINENT represents a unique collaborative network, funded up to £8M by the MRC matched in-kind by GSK.

Accessing GSK's clinic ready portfolio to enable translational discovery

Bringing together investigators from ¹û¶³Ó°Ôº (¹û¶³Ó°Ôº), the University of Cambridge, the University of Glasgow, the University of Newcastle, Imperial College London and GlaxoSmithKline (GSK), with unprecedented access to GSK's unlicenced clinic-ready asset portfolio to enable experimental medicine studies aimed at enhancing understanding of disease mechanisms and accelerating development of novel therapeutics for patients in under-served disease areas.